These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 21048203)

  • 21. A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.
    Moran M
    PLoS Med; 2005 Sep; 2(9):e302. PubMed ID: 16138789
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A new era of hope for the world's most neglected diseases.
    The
    PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PPPs succeeding in tackling neglected diseases.
    Frantz S
    Nat Rev Drug Discov; 2005 Oct; 4(10):796-7. PubMed ID: 16237841
    [No Abstract]   [Full Text] [Related]  

  • 24. Policymaking for Orphan Drugs and Its Challenges.
    Rhee TG
    AMA J Ethics; 2015 Aug; 17(8):776-9. PubMed ID: 26270879
    [No Abstract]   [Full Text] [Related]  

  • 25. [Orphan drugs : New opportunities for the treatment of rare diseases].
    Beck M
    Internist (Berl); 2016 Nov; 57(11):1132-1138. PubMed ID: 27527064
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Access to orphan drugs in Europe: current and future issues.
    Michel M; Toumi M
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [From drug cost to drug price: steps and decisional processes].
    Bruyninckx M; Nourissier C
    Presse Med; 2012 May; 41 Suppl 1():S40-3. PubMed ID: 22487715
    [No Abstract]   [Full Text] [Related]  

  • 28. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations.
    Vegter S; Rozenbaum MH; Postema R; Tolley K; Postma MJ
    Clin Ther; 2010 Aug; 32(9):1651-61. PubMed ID: 20974323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Orphan economics: the downside of supplyside pharmacology.
    Samson K
    Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
    [No Abstract]   [Full Text] [Related]  

  • 30. [Authorization and reimbursement of orphan drugs in an international comparison].
    Roll K; Stargardt T; Schreyögg J
    Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Financing R&D for neglected diseases.
    Herrling PL
    Nat Rev Drug Discov; 2009 Feb; 8(2):91. PubMed ID: 19189425
    [No Abstract]   [Full Text] [Related]  

  • 32. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O; Zhou Y
    Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Orphan drugs revisited.
    McCabe C; Tsuchiya A; Claxton K; Raftery J
    QJM; 2006 May; 99(5):341-5; discussion 350-1. PubMed ID: 16504983
    [No Abstract]   [Full Text] [Related]  

  • 34. Reforming the Orphan Drug Act for the 21st Century.
    Sarpatwari A; Kesselheim AS
    N Engl J Med; 2019 Jul; 381(2):106-108. PubMed ID: 31291512
    [No Abstract]   [Full Text] [Related]  

  • 35. Reducing the cost of rare disease drugs.
    Lancet; 2015 Feb; 385(9970):746. PubMed ID: 25752156
    [No Abstract]   [Full Text] [Related]  

  • 36. Adoption agents.
    Wapner J
    Sci Am; 2010 Jun; 302(6):19-20. PubMed ID: 20521471
    [No Abstract]   [Full Text] [Related]  

  • 37. How can the risk that orphan drugs present to budgets be managed better?
    O'Neill C
    Clin Ther; 2010 Aug; 32(9):1640-1. PubMed ID: 20974321
    [No Abstract]   [Full Text] [Related]  

  • 38. Uncommon ventures launch to tackle uncommon diseases.
    Dolgin E
    Nat Med; 2013 Aug; 19(8):950-1. PubMed ID: 23921728
    [No Abstract]   [Full Text] [Related]  

  • 39. The rising cost of orphan drugs.
    Lancet Haematol; 2015 Nov; 2(11):e456. PubMed ID: 26686251
    [No Abstract]   [Full Text] [Related]  

  • 40. [Drugs for rare diseases: the blessing of being orphans.].
    Costa E; Schieppati A; Luzzatto L; Remuzzi G
    Recenti Prog Med; 2019 May; 110(5):221-229. PubMed ID: 31140454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.